Grant: Engage Grants Program
Institut national de la recherche scientifique
$25,000.00
Small-molecule design for NMR fragment-based lead discovery
FY 2019-20
Summary
NMX is a translational contract research organization (CRO) located in Montreal and Boston. As part of the biopharmaceutical sector, NMX enables and accelerates small- molecule drug discovery by providing client-based services and partnerships for discovering hits and leads for future drugs. One of the most promising strategies for discovering our future medications is via fragment-based lead discovery (FBLD), an innovative technique exploited by NMX. FBLD involves the screening of libraries of small molecules to first identify weak binders to essential target proteins of diseases. These binders are then synthetically matured to larger, more potent inhibitors/leads via medicinal chemistry design efforts. However, there are major bottlenecks to achieving this critical step which have discouraged many pharmaceutical scientists from pursuing this approach. This is because experimental techniques are notoriously unreliable at properly characterizing weak binders at high concentrations. NMX proposes to tackle this issue by redefining the fundamental techniques at each step of FBLD. Libraries are designed, new NMR screening strategies are implemented and analysis software are developed. Together these efforts will enable medicinal chemists to easily establish structure-activity relationships (SAR), which is crucial for rendering binders to drug leads. However, in order to optimize results arising from these efforts, the implementation of NMR screening strategies cannot be achieved with the exclusive use of commercially available compounds. Moreover, the functionalization of bioactive molecules for further use in innovant applications (such as proteolysis targeting chimera, PROTAC) is complex, as it will not only require experience with the modification of bioactive molecules via SAR, but also with the careful design/synthesis of bifunctional linkers with the proper chemical functionalities to covalently link the most promising hits. Thus, there is a critical need to implement innovant synthetic strategies for the elaboration of modified fragments (hits) with superior drug-like properties, and Dr. Castonguay will bring an expertise in chemistry which is not currently available within the NMX team.
Program
Engage Grants Program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
543981-2019
Name nom
Castonguay, Annie
Department département
INRS-Institut Armand-Frappier, Centre
Organization id
56
Institution établissement
Institut national de la recherche scientifique
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2019
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Small-molecule design for NMR fragment-based lead discovery
Keyword
NSERC
Application summary
NMX is a translational contract research organization (CRO) located in Montreal and Boston. As part of the biopharmaceutical sector, NMX enables and accelerates small- molecule drug discovery by providing client-based services and partnerships for discovering hits and leads for future drugs. One of the most promising strategies for discovering our future medications is via fragment-based lead discovery (FBLD), an innovative technique exploited by NMX. FBLD involves the screening of libraries of small molecules to first identify weak binders to essential target proteins of diseases. These binders are then synthetically matured to larger, more potent inhibitors/leads via medicinal chemistry design efforts. However, there are major bottlenecks to achieving this critical step which have discouraged many pharmaceutical scientists from pursuing this approach. This is because experimental techniques are notoriously unreliable at properly characterizing weak binders at high concentrations. NMX proposes to tackle this issue by redefining the fundamental techniques at each step of FBLD. Libraries are designed, new NMR screening strategies are implemented and analysis software are developed. Together these efforts will enable medicinal chemists to easily establish structure-activity relationships (SAR), which is crucial for rendering binders to drug leads. However, in order to optimize results arising from these efforts, the implementation of NMR screening strategies cannot be achieved with the exclusive use of commercially available compounds. Moreover, the functionalization of bioactive molecules for further use in innovant applications (such as proteolysis targeting chimera, PROTAC) is complex, as it will not only require experience with the modification of bioactive molecules via SAR, but also with the careful design/synthesis of bifunctional linkers with the proper chemical functionalities to covalently link the most promising hits. Thus, there is a critical need to implement innovant synthetic strategies for the elaboration of modified fragments (hits) with superior drug-like properties, and Dr. Castonguay will bring an expertise in chemistry which is not currently available within the NMX team.